Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Delivery systems for pulmonary gene therapy.

Ajay Gautam1, Clifford J Waldrep, Charles L Densmore

  • 1Department of Molecular Physiology and Biophysics, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX 77030, USA.

American Journal of Respiratory Medicine : Drugs, Devices, and Other Interventions
|January 15, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

R&D productivity trends for biopharma companies in Asia and emerging markets.

Nature reviews. Drug discovery·2026
Same author

Synergistic use of ICESat-2 lidar data and Sentinel-2 imagery for assessing hurricane-driven forest changes.

Environmental monitoring and assessment·2025
Same author

Multifunctional ion-conductive polymer coatings for high-performance sulfide solid-state batteries with Ni-rich cathodes.

Journal of materials chemistry. A·2025
Same author

Life science ecosystems in Asia: biomedical innovation trends over the past decade.

Nature reviews. Drug discovery·2025
Same author

Decoding Structural Disorder, Synthesis Methods, and Short- and Long-Range Lithium-Ion Transport in Lithium Argyrodites (Li<sub>6-</sub> PS<sub>5-</sub> Br<sub>1+</sub> ).

Chemistry of materials : a publication of the American Chemical Society·2025
Same author

A tale of two ecosystems: the biopharma landscape in China and India.

Nature reviews. Drug discovery·2024
Same journal

Long-acting beta2-agonists: comparative pharmacology and clinical outcomes.

American journal of respiratory medicine : drugs, devices, and other interventions·2004
Same journal

Asthma refractory to glucocorticoids: the role of newer immunosuppressants.

American journal of respiratory medicine : drugs, devices, and other interventions·2004
Same journal

Second-generation antihistamines in asthma therapy: is there a protective effect?

American journal of respiratory medicine : drugs, devices, and other interventions·2004
Same journal

The role of interleukin-8 and its receptors in inflammatory lung disease: implications for therapy.

American journal of respiratory medicine : drugs, devices, and other interventions·2004
Same journal

Thromboxane A2 inhibition: therapeutic potential in bronchial asthma.

American journal of respiratory medicine : drugs, devices, and other interventions·2004
Same journal

Influenza vaccination: is it appropriate in chronic fatigue syndrome?

American journal of respiratory medicine : drugs, devices, and other interventions·2004
See all related articles

Gene therapy offers a promising approach for treating lung diseases like cystic fibrosis and cancer by delivering therapeutic genes. Overcoming delivery barriers and immune responses is key to improving treatment efficacy and safety.

Area of Science:

  • Pulmonary medicine
  • Gene therapy
  • Biotechnology

Background:

  • Gene therapy is a promising strategy for treating various pulmonary dysfunctions, including cystic fibrosis, alpha-1 antitrypsin deficiency, pulmonary hypertension, asthma, and lung cancer.
  • Different delivery routes (intratracheal, aerosol, intravenous) and vector types (viral, non-viral) have been explored for lung gene delivery, achieving varying levels of transgene expression.

Purpose of the Study:

  • To review the current state of gene therapy for pulmonary diseases.
  • To identify challenges and progress in overcoming barriers to effective lung gene delivery.

Main Methods:

  • Review of existing literature on pulmonary gene therapy delivery methods and vector systems.
  • Analysis of barriers encountered during gene delivery to the lungs, including biological and immunological factors.

Related Experiment Videos

Main Results:

  • Significant transgene expression has been achieved using both viral and non-viral vectors in the lungs.
  • Key barriers to pulmonary gene therapy include serum proteins, surfactant and mucus in the airways, and immune/cytokine responses.

Conclusions:

  • Despite challenges, substantial progress has been made in enhancing the efficiency and reducing the toxicity of gene therapy vectors for pulmonary disorders.
  • Further research is needed to optimize delivery systems and overcome biological hurdles for successful clinical application in lung diseases.